LONDON, March 23 -- The government of the United Kingdom issued the following news:
As a precautionary measure,Molnlycke Health Careisrecallingthreebatches of Hibiwash, an antimicrobial wash,due tomicrobialcontamination at the manufacturing facility.
ContaminationwithBurkholderiacepaciawasidentifiedduringroutine weekly monitoring,butthere have been no reports of patient harm.
The risk fromBurkholderiacepaciaisvery lowformost people, but some patient groups are at a higher risk andmay bemore vulnerable to infection. This includes patientswho have cystic fibrosisorareawaiting lung transplant. There have currently been no confirmed cases of Burkholderia cepacia infection in patients from the affected batches.
Healthcare professionalsand retailers should stop supplying Hibiwash withbatch numbers 5156042, 5156043, and 5156093and return all remaining stock to suppliers. Patientsshould check for the batch number on the bottle and those who have an impacted batch of Hibiwashshouldstop using it.Patientswith cystic fibrosis orwhoareawaiting lung transplant who have been supplied withHibiwashsince 10 February2026willbe contacted directly to check if theyhavean impacted batch.If you have not been contacted directly, then contact the team responsible for yourcare..
Alternativechlorhexidinegluconate4% washes are available and are notimpactedby this recall.
Shareen Doak, Deputy Director, Benefit-Risk Evaluation, at theMedicines and Healthcare products Regulatory Agency (MHRA)said:
"If youhaveHibiwash, check the packaging forbatch numbers 5156042, 5156043or5156093and stop using it. These batches could be contaminated with Burkholderiacepaciaand should betaken to a pharmacy for safe disposal.
"Please be reassured thatthere have been no reports ofpatient harmassociated withthis microbial contamination,and thisrecall is being carried out as a precaution.
"If youhave used the product andare concerned that youmay bevulnerable to infection orhave experienced an adverse reaction,please seek medical advice.
"Any suspected adverse reactionscan be reported to the MHRA through theMHRA'sYellow Card Schemescheme."
Notes to editors
*
Please seeMHRA's Class 2 recallfor further information.
*
This recall impactsaround50,000 units ofHibiwash
*
The MHRAis responsible forregulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
*
The MHRA is an executive agency of the Department of Health and Social Care.
*
For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.
Disclaimer: Curated by HT Syndication.
